Medical/Pharmaceuticals
Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published
JINAN, China, Nov. 6, 2023 /PRNewswire/ -- Recently, the results of the Phase I study for iparomlimab (R&D code: QL1604), developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journalFrontiers in Immunology (2022 Impact Factor: 7.3). The title of the paper is "A first-i...
2023-11-06 18:54
1623
Novogene AMEA adopts Olink® Explore HT platform
SINGAPORE, Nov. 6, 2023 /PRNewswire/ -- Novogene Asia Pacific Middle East and Africa (AMEA), a leading provider of genomic services and solutions is pleased to announce the adoption of the Olink® Explore HT platform. The addition of Olink Explore HT enhances Novogene AMEA's capabilities and qual...
2023-11-06 18:00
1826
'Listen to your patients for early identification of Peripheral Neuropathy' say leading Health Experts at P&G's #KNOWTHESIGNS Scientific Forum
* 1 in 2 Diabetics and 1 in 10 Pre-diabetics estimated to suffer from PN * Vitamin B Deficiency affects quality of life of ~ 19% of all Diabetics * Unveil NEW NENOIN Study results on how B Vitamins improve sensory symptoms, motor function and motor strength in PN JAKARTA, Indonesia, Nov. 6, 2...
2023-11-06 17:07
1845
Meet Joey Rabbit, the New AI-Powered 3D Virtual Mental Health Butler from Bamboo Technology
Debuts at 4th anniversary celebration of company's mental health app Here Hear, organized around World Mental Health Day 2023 TAIPEI, Nov. 6, 2023 /PRNewswire/ -- Bamboo Technology, a mental health technology innovation company, is thrilled to unveil Joey Rabbit, a state-of-the-art 3D virtual me...
2023-11-06 16:21
1561
The Farrer Park Company Pte Ltd Appoints Ms Kelly Yang as Chief Executive Officer of Farrer Park Hospital
SINGAPORE, Nov. 6, 2023 /PRNewswire/ -- The Farrer Park Company Pte Ltd is pleased to announce the appointment of MsKelly Yang as the Chief Executive Officer (CEO) of Farrer Park Hospital (FPH). Ms Yang will succeed DrTimothy Low , the outgoing CEO, who is leaving to pursue other healthcare ventur...
2023-11-06 12:27
2063
Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the safety, pharmacokinetics (PK), and pharmacodynamics (PD) data of ASC42, a novel farnesoid X receptor (FXR) agonist, in healthy subjects ha...
2023-11-06 12:20
1930
The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval
YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug...
2023-11-06 09:11
1539
XtalPi and CK Life Sciences Ink Agreement to Develop Cancer Molecular Diagnostic Models using AI and Biomarker Data
SHENZHEN, China, Nov. 6, 2023 /PRNewswire/ -- Today, XtalPi, a leading global technology company in combining artificial intelligence (AI) and robotics to drive the discovery of groundbreaking medicine and innovative materials, announced the signing of a new agreement with CK Life Sciences, a mem...
2023-11-06 09:00
2188
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-11-06 08:00
2912
Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy
SHANGHAI, Nov. 4, 2023 /PRNewswire/ -- On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application (IND) for KGX101. KGX101 is a recombinant IL-12 Fc fusion protein designed for intravenous injection. The KGX101 clin...
2023-11-05 08:00
2490
Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America
Pierre Fabre Laboratories to Acquire from Atara Biotherapeutics Commercialization Rights to EBVALLO® in the United States, Canada and All Remaining Markets Pierre Fabre Laboratories to Take Over All Manufacturing, Clinical, and Regulatory Activities for EBVALLO® Following Transition Period This...
2023-11-04 00:52
1992
Verismo Therapeutics Announces Upcoming Presentation at SITC 2023
PHILADELPHIA, Nov. 3, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology today announced that it will be presenting at the upcoming Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023), to be held in San Diego and ...
2023-11-03 21:00
2189
Mediwave Unveils AI-Powered Emergency Response Suite and Smart Ambulance with Mixed Reality Tech in Malaysia
SINGAPORE, Nov. 2, 2023 /PRNewswire/ -- Mediwave, an emerging leader in healthcare technology, marked a significant milestone with the introduction of its cutting-edge end-to-end Emergency Response suite and the Smart Connected Ambulance, featuring AI and Mixed Reality technology inMalaysia. This...
2023-11-03 13:59
1563
The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan
HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao,Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, indust...
2023-11-03 12:10
814
ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM
SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from three clinical studies of lisaft...
2023-11-03 09:15
798
ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the ...
2023-11-03 09:10
704
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...
2023-11-03 05:15
605
Frost & Sullivan Honors Komodo Health with Technology Innovation Leadership Award for Its Data-Driven Platform to Improve Patient Care
Komodo Health Delivers In-Depth and Actionable Patient-Level Insights for Enterprise Customers with its Robust Real-world Data, Advanced Analytics and AI-powered Algorithms, and Clinical and Industry Expertise SAN ANTONIO and SAN FRANCISCO, Nov. 2, 2023 /PRNewswire/ -- Frost & Sullivan recently ...
2023-11-02 23:48
1255
Complete Genomics and Basepair™ Announce Technology Integration Partnership
SAN JOSE, Calif. and NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Complete Genomics and Basepair, Inc today announced a technology integration partnership to accelerate the analysis and interpretation of genomic data generated by Complete Genomics' DNBSEQTM sequencing platforms*. The partnership gives ...
2023-11-02 21:00
1106
Lion TCR clinched the prestigious T-Up Excellence Awards in Singapore
SINGAPORE, Nov. 2, 2023 /PRNewswire/ -- At the annual Singapore Week of Innovation and Technology (SWITCH) 2023, Lion TCR, a clinical-stage mRNA-based T cell immunotherapy company, is thrilled to announce a significant milestoneof clinching the T-Up Excellence Awards. This award, in recognitio...
2023-11-02 20:41
2183
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 305 media titles]
2025-01-06 14:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 293 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 290 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10771
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
2025-01-02 08:16
8345
PieX AI: Launching the World's First Personalized, On-device AI Pendant at CES 2025
2025-01-02 21:00
6750
